Coya Therapeutics’ COYA 301 (interleukin-2) Shows Promising Results in Open Label Alzheimer’s Study
Coya Therapeutics’ investigational low-dose interleukin-2 (IL-2) for subcutaneous administration, COYA 301, has been found to increase Treg function and halt
Read more